Keywords: Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Hepatocellular cancer; Target therapies; Second line; Everolimus; Ramucirumab;
Keywords: Angiogenesis; Bevacizumab; Aflibercept; Ramucirumab; Second line; Colorectal cancer;
Keywords: Angiogenesis; Advanced gastric cancer; Bevacizumab; Ramucirumab
Ramucirumab in patients with advanced gastric and gastroesophageal junction cancer: Learnings from East Asian data
Keywords: Anti-angiogenesis; Gastric cancer; Gastroesophageal junction adenocarcinoma; Ramucirumab; Taiwan;
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
Keywords: Advanced gastric cancer; Nab-paclitaxel; Paclitaxel; Ramucirumab; Overall response rate; Second-line chemotherapy;
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Keywords: CI; confidence interval; DCR; disease control rate; DOC; docetaxel; EMA; European Medicines Agency; FDA; US Food and Drug Administration; HR; hazard ratio; ITT; intent to treat; NSCLC; non-small cell lung cancer; OR; odds ratio; ORR; objective response ra
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Keywords: Human monoclonal antibody; Non-small cell lung cancer (NSCLC); Ramucirumab; Refractory patients; Vascular endothelial growth factor (VEGF); Docetaxel; Clinical trial; Histology; Angiogenesis; Phase 3 clinical trial;
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group
Keywords: Non squamous NSCLC; Second line therapy; Nintedanib; Ramucirumab; Nivolumab; Pembrolizumab; Atezolizumab; Docetaxel; Therapeutic strategy;
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
Keywords: Non-small-cell lung cancer; Histology; Ramucirumab; Docetaxel;
Original ResearchRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Keywords: Ramucirumab; Sorafenib; Hepatocellular carcinoma; Patient-focused outcomes; Quality of life; Performance status;
Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan
Keywords: cost-effectiveness; gastric cancer; Markov model; paclitaxel; ramucirumab;
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
Keywords: Metastatic; Colorectal carcinoma; Carcinoembryonic antigen; CEA; Predictive; Ramucirumab; Phase III clinical trial;
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
Keywords: Epidermal growth factor receptor mutation; Erlotinib; Non-small cell lung cancer; Ramucirumab; RELAY trial;
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Keywords: AE; adverse event; CI; confidence interval; CR; complete response; CT; computed tomography; DCR; disease control rate; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; FAS; full analysis set; HR; hazard ratio; ILD; interst
Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents
Keywords: Ramucirumab; Hypertension; Bleeding; Thrombosis
Associate editor: B. PatelAntagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Keywords: Tumor vasculature; Angiogenesis; Endothelial cell; VEGFR-2; Ramucirumab; DC101; Ang1; angiopoietin 1; Ang2; angiopoietin 2; bFGF; basic fibroblast growth factor; CEP; circulating endothelial progenitor cells; DCE-CT; dynamic contrast-enhanced computerized
Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects
Keywords: Gastric cancer; VEGF; Bevacizumab; Ramucirumab
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
Keywords: Ramucirumab; Cixutumumab; Mitoxantrone; Prednisone; Prostate cancer;
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective
Keywords: Metastatic colorectal cancer; Bevacizumab; Ziv-aflibercept; Regorafenib; Angiogenesis; Ramucirumab; Antiangiogenic;
A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
Keywords: Angiogenesis; Lung cancer; Ramucirumab; Paclitaxel; Carboplatin;
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
Keywords: Metastatic melanoma; Phase II; Ramucirumab
A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale an
Keywords: NSCLC; Previously treated; Ramucirumab; VEGF